A case of COVID ‐19‐associated mucormycosis due to Lichtheimia ramosa
Journal of Clinical Laboratory Analysis · 2023
DOI: 10.1002/jcla.24895 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Laboratory Analysis, 2023. Verfasst von Shima Aboutalebian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Mucormycosis, COVID-19, Mucorales. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mucormycosis is a life‐threatening invasive fungal infection in immunocompromised and COVID‐19 patients. Case Report Here, we report a fatal rhino‐orbito‐cerebral mucormycosis caused by Lichtheimia ramosa, in a 79‐year‐old diabetic female. She was initially admitted to the hospital for COVID‐19 infection and received broad‐spectrum antibiotics and corticosteroids. After 1 month, she was admitted again because of persistent headaches and decreased right eye movement when the computed tomography scan showed mucosal thickening and opacification of paranasal sinuses. Microbiological investigations, including culture and direct microscopy, and histopathological findings confirmed the diagnosis of proven mucormycosis. The isolated causal agent was identified as Lichtheimia ramosa by sequencing the entire ITS region of nuclear ribosomal DNA. Despite surgical debridement and administration of liposomal amphotericin B 5 mg/kg/day, the patient's level of consciousness suddenly deteriorated; she was intubated and mechanically ventilated in the ICU and died on the same day.
Conclusion
To our knowledge, this is the first worldwide case of COVID‐19‐associated rhino‐orbito‐cerebral mucormycosis due to Lichtheimia ramosa .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
- Mycology Reference Laboratory, Research Core Facilities Laboratory, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Infectious Disease, School of Medicine, Shahid Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran.
- Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
- Immunology, Asthma, and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Pathology and Histology, School of Medicine, Shahid Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran.
ORCID-Profile: Shima Aboutalebian, Hossein Mirhendi
Zitieren
APA
Aboutalebian, S., Erami, M., Momen-Heravi, M., Charsizadeh, A., Hezaveh, S. J. H., Matini, A. H., Ahsaniarani, A. H., Fakhrehi, M., & Mirhendi, H. (2023). A case of COVID ‐19‐associated mucormycosis due to Lichtheimia ramosa. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.24895
Vancouver
Aboutalebian S, Erami M, Momen-Heravi M, Charsizadeh A, Hezaveh SJH, Matini AH, et al. A case of COVID ‐19‐associated mucormycosis due to Lichtheimia ramosa. Journal of Clinical Laboratory Analysis. 2023. doi:10.1002/jcla.24895
BibTeX
@article{Aboutalebian2023,
author = {Aboutalebian, Shima and Erami, Mahzad and Momen-Heravi, Mansooreh and Charsizadeh, Arezoo and Hezaveh, Seyed Jamal Hashemi and Matini, Amir Hassan and Ahsaniarani, Amir Hossein and Fakhrehi, Mojtaba and Mirhendi, Hossein},
title = {A case of COVID ‐19‐associated mucormycosis due to Lichtheimia ramosa},
journal = {Journal of Clinical Laboratory Analysis},
year = {2023},
doi = {10.1002/jcla.24895}
}
EUVIMED